Loading stock data…
STOK
$33.08+0.36 (+1.10%)
Market ClosedLast close May 1
Stoke Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Stoke Therapeutics, Inc. in the Healthcare sector is trading at $33.08. The stock is currently 18% below its 52-week high of $40.22, remaining 17.1% above its 200-day moving average. Technical signals show neutral RSI of 39 and bearish MACD signal, explaining why STOK maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 39) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$33.08
Potential Upside
5%
Whystock Fair Value$34.73
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$45.10+36.3%
Range$35.00 – $60.00
Fundamentals
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisen...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.12B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.22
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
14.89%
Volume
Today's trading volume
452,297
Recent News
Stoke Therapeutics Auditor Switch Puts Biotech Governance In Focus
Stoke Therapeutics (NasdaqGS:STOK) has changed its independent auditor from KPMG LLP to Ernst & Young LLP. The auditor transition was recently approved by the company and disclosed as a corporate governance event. The change affects future audit engagements and oversight of the company’s financial reporting. Stoke Therapeutics focuses on genetic medicines, an area that continues to attract attention as new RNA and gene based approaches move through research and development. For investors...
Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets
In an interview, Chief Financial Officer Robin Kramer said the combined cash flow from Biogen and Apellis will not only help debt leverage ratios but also free up capacity to do other strategic deals.
Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares
This biotech innovator in genetic disease therapies reported a notable insider sale amid a year of dramatic share price gains.
Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally
This RNA therapeutics innovator for rare diseases reported a notable insider sale amid a year of dramatic share price gains.
Biogen Rare Disease Data And Valuation Discount Draw Investor Attention
Biogen (NasdaqGS:BIIB) reported one year results for salanersen in children with spinal muscular atrophy, showing clinical improvements and reduced neurodegeneration markers after once yearly dosing. The company outlined the initiation and design of a global Phase 3 program for salanersen in spinal muscular atrophy. Separately, Biogen and Stoke Therapeutics released data on zorevunersen indicating potential disease modification in Dravet syndrome. For investors watching NasdaqGS:BIIB, these...